Mainz Biomed BV (MYNZ) — Strategic Asset Allocation Index

Latest as of June 2022: 3.4%

Mainz Biomed BV (MYNZ) has a Strategic Asset Allocation Index of 3.4% as of June 2022. Strategic assets (PP&E of $805.51K plus long-term investments of $-) total $805.51K, measured against net assets of $23.77 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Mainz Biomed BV balance sheet quality to measure how much of total assets are equity-financed.

SAAI

3.4%
Strategic Assets / Net Assets

Strategic Assets

$805.51K
PP&E + LT Investments

PP&E

$805.51K
USD

Net Assets

$23.77 Million
USD

Mainz Biomed BV Strategic Asset Allocation Index (2021–2021)

This chart shows how Mainz Biomed BV's Strategic Asset Allocation Index has evolved across 1 annual periods from 2021 to 2021. As of June 2022, the index stands at 3.4%, representing strategic assets of $805.51K against net assets of $23.77 Million USD. For live market cap and overall valuation, see market value of Mainz Biomed BV.

Annual Strategic Asset Allocation Index for Mainz Biomed BV (2021–2021)

The table below presents the year-by-year Strategic Asset Allocation Index for Mainz Biomed BV from 2021 to 2021, covering 1 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See MYNZ total equity for net asset value and shareholders' equity analysis.

Year SAAI Strategic Assets (USD) PP&E LT Investments Net Assets Change (pp)
2021 6.8% $431.59K $431.59K $- $6.36 Million
pp = percentage points